1271-P: Health Care Utilization and Cost with Empagliflozin vs. GLP-1RA in Patients with Type 2 Diabetes

Introduction & Objective: Despite the established cardiovascular benefits of empagliflozin (EMPA) and glucagon-like peptide-1 receptor agonists (GLP-1RA), questions remain on their impact on healthcare resource utilization (HCRU) and costs. Methods: Using US Medicare fee-for-service (FFS) and Op...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Diabetes (New York, N.Y.) N.Y.), 2024-06, Vol.73, p.1
Hauptverfasser:	Htoo, Phyo T, Tesfaye, Helen, Wexler, Deborah J, Glynn, Robert, Schmedt, Niklas, Koeneman, Lisette, Paik, Julie M, Patorno, Elisabetta
Format:	Artikel
Sprache:	eng
Schlagworte:	Antidiabetics Cardiovascular diseases Costs Diabetes Diabetes mellitus (non-insulin dependent) Emergency medical care GLP-1 receptor agonists Glucagon Glucagon-like peptide 1 Health care Pharmacy Resource utilization
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!